Expertise in
20
conditions

Dr. Shayma M. Kazmi

Oncology
1865 Route 70 East, 
Cherry Hill, NJ 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
20
conditions
1865 Route 70 East, 
Cherry Hill, NJ 

Overview

Shayma Kazmi is an Oncologist practicing medicine in Cherry Hill, New Jersey.

Dr. Kazmi is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and Squamous Cell Lung Carcinoma.

Dr. Kazmi is board certified in Internal Medicine, 2004, Medical Oncology, 2007, and Hematology, 2007. She is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 3 clinical trials. Dr. Kazmi is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in NJ

Board Certifications

Internal Medicine, 2004
Medical Oncology, 2007
Hematology, 2007

Hospital Affiliations

Hospital Of Univ Of Pennsylvania
West Jersey Hospital
Penn Presbyterian Medical Center
Virtua Our Lady Of Lourdes Hospital

Languages Spoken

English
Hindi

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Provider Partners Health Plan
  • MEDICARE SNP
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Abramson Cancer Center Cherry Hill
1865 Route 70 East, Cherry Hill, NJ 8003.
Other Locations
Penn Hematology/Oncology Sewell
239 Hurffville-Cross Keys Road, Suite 130, Sewell, NJ 8080.

Additional Areas of Focus

Dr. Kazmi has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Lung Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Enrollment Status: Terminated
Publish Date: April 23, 2026
Intervention Type: Drug
Study Drugs: Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Study Phase: Phase 2
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 2 Less Clinical Trials

3 Total Publications

Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Journal: Breast cancer research and treatment
Published: April 28, 2021
Similar Doctors
Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

University Of Pennsylvania

3400 Civic Center Blvd, 
Philadelphia, PA 
 (8.7 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jakub Svoboda is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Svoboda is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Classical Hodgkin Lymphoma, B-Cell Lymphoma, and Bone Marrow Aspiration.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required
Before you request

Penn Mesothelioma And Pleural Program

51 N. 39th Street, Pavilion For Advanced Care, First Floor, 
Philadelphia, PA 
 (9.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Corey Langer is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Langer is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Langer is board certified in Hematology, 1986, Medical Oncology, 1987, and Internal Medicine, 1984. Dr. Langer is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required
Before you request

Abramson Cancer Center Perelman 2nd Floor West

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (8.6 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arati Desai is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Desai is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri. Dr. Desai is board certified in Medical Oncology, 2008, Hospice And Palliative Medicine, 2012, and Internal Medicine, 2004. Dr. Desai is currently accepting new patients.

Frequently Asked Questions about Dr. Shayma M. Kazmi

How do I make an appointment with Dr. Shayma M. Kazmi?

You can book an appointment with Dr. Shayma M. Kazmi by calling their office at 800-789-7366. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Shayma M. Kazmi a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Shayma M. Kazmi is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Shayma M. Kazmi specialize in?

While Dr. Shayma M. Kazmi is a Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Shayma M. Kazmi participate in research or clinical trials?

Yes. Dr. Shayma M. Kazmi has published 3 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Shayma M. Kazmi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Shayma M. Kazmi accept my insurance?

Dr. Shayma M. Kazmi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 800-789-7366 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kazmi's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 9 Advanced Conditions
    View All 93 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile